eyeforpharma
To download this exclusive whitepaper fill out the below form:
Email Address*

First Name*
Country*
Business Type*

Rethink your business model with payers in mind

Show me the Evidence Whitepaper

Get the information you need to ensure your European market access strategy is heading in the right direction.

It was less than a decade ago that most pharmaceutical manufacturers considered market access the last step in the commercialization process. However access is being managed ever more tightly with payers increasingly establishing evidence-based care paths and therapeutic guidelines.

Payers are now a significant player in product commercialization and companies need to rethink their business models. In this white paper we explore how the G-5 European countries have faced these challenges.


These +15 pages will give you:

  • Specific processes: How reimbursement and pricing are outlined, as well as the approach for determining “additional medical benefit” for premium pricing. 
  • Interviews from payers and HTAs: They explain how they operate and how best to approach them
  • Individual reimbursement: An update on each process and future trends, what data to use for successful negotiation and how to retrieve it 
  • Real world examples: Of How to build your Economic and Clinical Value (ECV) story
Paul Simms
Chairman
eyeforpharma
psimms@eyeforpharma.com